Generic Name and Formulations:
Nesiritide 1.5mg/vial; pwd for IV inj after reconstitution and dilution; contains mannitol.
Indications for NATRECOR:
Acutely decompensated CHF with dyspnea at rest or with minimal activity.
2mcg/kg IV bolus once, then 0.01mcg/kg per minute by continuous IV infusion; limited experience with therapy >96 hours. Doses up to 0.03mcg/kg per minute have been used; see full labeling. Reduce dose or discontinue if symptomatic hypotension occurs.
Persistent systolic BP <100mmHg. Cardiogenic shock.
Not recommended in significant valvular stenosis, restrictive or obstructive cardiomyopathy, constrictive pericarditis, pericardial tamponade, other conditions where vasodilators are inappropriate, or when cardiac output is dependent on venous return, or in patients with low cardiac filling pressures. Impaired renal function (esp if severe heart failure); monitor serum creatinine during and after therapy until stabilized. Monitor BP closely. Pregnancy (Cat.C). Nursing mothers.
Vasodilator (human B-type natriuretic peptide).
Hypotension potentiated by ARBs and/or ACE inhibitors.
Hypotension, headache, nausea, back pain, dizziness; hypersensitivity.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)